Based on a report supported by Bettegowda et al. (21), the sensitivity of ctDNA was 87.2% for detection of clinically relevant KRAS gene mutations, with specificity of 99.2% in the detection of metastatic cancers. Here, KRAS is linked to metastatic malignant neoplasm.